Shopping Cart
- Remove All
- Your shopping cart is currently empty
BMS-737 (compound 33), a non-steroidal, reversible small molecule inhibitor, demonstrates 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase. This compound is engineered to target castration-resistant prostate cancer (CRPC) and effectively lowers testosterone levels, while maintaining stable orrodermal hormone and glucocorticoid levels.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | BMS-737 (compound 33), a non-steroidal, reversible small molecule inhibitor, demonstrates 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase. This compound is engineered to target castration-resistant prostate cancer (CRPC) and effectively lowers testosterone levels, while maintaining stable orrodermal hormone and glucocorticoid levels. |
Molecular Weight | 306.30 |
Formula | C16H11FN6 |
Cas No. | 1356053-63-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.